No Data
Shanghai RAAS Blood Products (002252.SZ): Subsidiary received pharmaceutical registration verification notification.
Grain Weekly, December 3rd | Shanghai Raas Blood Products (002252.SZ) announced that its wholly-owned subsidiary Tonglu Biopharmaceutical Co., Ltd. recently received the "Notice on Initiating Registration Verification of Human Fibrinogen Drugs (Clinical)" and the "Notice on Initiating Registration Verification of Human Fibrinogen Drugs (Pharmaceutical)" issued by the Drug Evaluation Center of the National Medical Products Administration. According to the relevant provisions of the Drug Registration Management Measures, the Drug Evaluation Center needs to conduct registration verification of the human fibrinogen starting drug declared by Tonglu Biopharmaceutical. Human fibrinogen is produced from healthy human plasma, separated, purified, and subjected to virus removal, inactivation treatment, and freeze-drying.
RAAS Blood Products Gets China Approval for Clinical Trial of Human Fibrinogen
Shanghai RAAS Blood Products (002252.SZ): The clinical trial application for human fibronectin raw pharmaceutical materials has been accepted.
Gelonghui, November 27th丨Shanghai raas blood products (002252.SZ) announced that its wholly-owned subsidiary, Zhengzhou Raas Blood Products Co., Ltd., recently received two acceptance notices from the National Medical Products Administration regarding the clinical trial application for "human fibrinogen", namely the "Acceptance Notice" (Acceptance No: CXSL2400799) and the "Acceptance Notice" (Acceptance No: CXSL2400800). This product is made from healthy human plasma, separated and purified, and treated with virus removal and inactivation, then freeze-dried. Glycine and hydrochloric acid arginine are used as stabilizers, without bacteriostatic agents and antibiotics.
Selected Announcement | China Petroleum & Chemical Corporation: The net income in the first three quarters was 44.247 billion yuan, a year-on-year decrease of 16.5%; Beijing Oriental Yuhong Waterproof Technology: planning to invest 0.5 billion yuan to -1
Three Squirrels Inc. plans to increase investment in building snack supply chain and intensive bases.
Shanghai Laishi: Report for the third quarter of 2024
shanghai raas blood products (002252.SZ): net income for the first three quarters was 1.838 billion yuan, a year-on-year increase of 2.81%.
GeLongHui October 28th | Shanghai RAAS Blood Products (002252.SZ) released the third quarter report for 2024, achieving revenue of 6.314 billion yuan in the first three quarters, a year-on-year increase of 6.39%; net income attributable to the shareholders of the listed company was 1.838 billion yuan, a year-on-year increase of 2.81%; net income attributable to the shareholders of the listed company after deducting non-recurring gains and losses was 1.739 billion yuan, a year-on-year decrease of 3.64%; basic earnings per share was 0.277 yuan.